THERAPY DOSSIER · th-1ed3a63a9539

Codium fragile butanol and ethyl acetate fractions and the isolated compound clerosterol

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23396144 ↗2013Reported benefit

Protective effect of Codium fragile against UVB-induced pro-inflammatory and oxidative damages in HaCaT cells and BALB/c mice.

MouseRadiationBALB/cMaleTopical application to skinApplied prior to UVB irradiation

Model: UVB irradiation of skin at 200 mJ/cm2 in vivo and 60 mJ/cm2 in HaCaT keratinocytes

Topical Codium fragile fractions and clerosterol inhibited UVB-induced increases in COX-2, iNOS and TNF-alpha and reduced lipid peroxidation and protein carbonylation in mouse skin, mirroring protection seen in HaCaT cells.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…